Lung Cancer Considered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice. Guests: Hina Khan, MD Thoracic Oncologist Assistant Professor of Medicine Warren Alpert Medical School, Brown University Corey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer Center Professor of Medicine , Perelman School of Medicine University of Pennsylvania

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC. Guests: Kelsey Pan, MD, MPH Assistant Professor of Medicine Department of Hematology & Oncology, Thoracic Medical Oncology Section Emory University Winship Cancer Institute Rajat Thawani, MD Assistant Professor of Medicine Division of Hematology and Oncology Knight Cancer Institute, OHSU

This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy

This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale. Host: Dr. Stephen Liu Guests: Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology. Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of Melbourne Dr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert cardiothoracic surgeons, Dr. Ben Li, Professor from The First Affiliated Hospital of Guangzhou Medical University and, and Dr. Calvin Ng, Professor from the Chinese University of Hong Kong. The discussion: reviews surgical management of early-stage NSCLC, including VATS, and lobar versus sublobar resection; and explores novel technologies including endobronchial therapy and tubeless anesthesia. Host: Molly Li, MD Clinical Assistant Professor Department of Clinical Oncology, CUHK, Hong Kong Guests: Shuben Li, MD, PhD Professor, Department of Thoracic Surgery National Center for Respiratory Medicine The First Affiliated Hospital of Guangzhou Medical University Calvin S.H. Ng, BSc MBBS, MD Environmental Foundation Professor of Thoracic Surgery Department of Surgery The Chinese University of Hong Kong (CUHK)

This episode of Lung Cancer Considered examines how artificial intelligence is being incorporated into patient care and what the future holds for this emerging technology. We will be discussing: • Is AI the right move for oncology care? • What is the impact on patient care and our patient expert's experience? • And how can we learn more about AI? Guest: Dr. Sandip Patel, is a professor of Medicine at UCSD and a nationally recognized leader in precision cancer medicine and innovation. He specializes in early-phase clinical trials and immunotherapy, with a focus on developing innovative treatments for patients with advanced lung cancer. Today, we're excited to welcome him to the podcast to discuss the future of AI in cancer care, in general, and in thoracic oncology in particular.

This episode of Lung Cancer Considered, hosted by Dr. Narjust Florez, examines the challenges of delivering lung cancer care in areas affected by war and displacement with guests Dr. Julie Gralow and Dr. Rafal Dziadziuszko. The discussion addresses disrupted diagnosis and treatment, heightened inequities, and unique environmental exposures that may increase lung cancer risk in conflict settings. The episode also highlights emerging opportunities through global collaboration, adaptable care models, and shared responsibility across the oncology community. Guests: Dr. Julie Gralow, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO). She is also the founder of the Women's Empowerment Cancer Advocacy Network (WE CAN) and an expert in global oncology. Rafał Dziadziuszko, M.D., Ph.D., professor of medicine, Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk in Poland

As part of IASLC's ongoing series of Lung Cancer Considered podcast episodes in world languages, Dr. Ece Cali moderates a discussion in Turkish with Dr. Irfan Çiçin and Dr. Fulden Yumuk. The episode is part of our Virtual Tumor Board series and focuses on immunotherapy for non-small cell lung cancer (NSCLC).

This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease. Guests: Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer. Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.

As part of IASLC's Lung Cancer Considered World Language Series, guest host Dr. Maria Cecilia Mathias leads a discussion in Portuguese about the junior faculty perspective with Dr. Maria Thereza Starling and Dr. Paula Duarte.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by CNN Medical Correspondent Meg Tirrell and WTOP reporter Neal Augenstein to discuss the role of the media in lung cancer awareness and perception. Traditional media, including television and radio, do much to shape the public perception of lung cancer and healthcare in general. Meg Tirrell and Neal Augenstein share their experiences reporting in the health sector, establishing trust with their audiences in the face of uncertainty, and distilling complex medical information to the general public.

Since the first immunotherapy agent for lung cancer was approved in 2015, this class of drugs has captured the imagination and the narrative for the treatment of driver negative lung cancer. Immunotherapy is now the standard of care for most patients with lung cancer in some form. And while not all patients benefit, those that do, have the chance for transformative benefit. In today's episode, we focus not on the benefit of immunotherapy, which can be massive, but on the toxicity of immunotherapy. Guest: Dr. Jarushka Naidoo, a consultant medical oncologist at Beaumont Hospital Dublin and a Professor in the Royal College of Surgeons in Ireland. She currently serves as national lung cancer lead for Cancer Trials Ireland and serves on several international guideline panels including ASCO and SITC

The FDA has approved subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.

In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the IASLC | ASCO 2025 North America Conference on Lung Cancer. Dr. Igor Odintsov discusses updates in diagnostic pathology, including the integration of next-gen sequencing into the patient's journey. Dr. Byoung Chul Cho shares data from the phase 3 trial of gotistobart vs. docetaxel in patients with metastatic squamous cell lung cancer. Dr. Sulin Wu shares insights on the role of family history in lung cancer among women and low-exposure smokers.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with two thoracic oncologists practicing in New Zealand—Dr. Laird Cameron from Auckland Hospital and Dr. Annie Wong from the University of Otago—about the unique challenges and approaches to lung cancer care in their island nation of 5.4 million people. The conversation explores New Zealand's healthcare coverage system, patient population characteristics including smoking rates, the current state of lung cancer screening programs, and how molecular testing is conducted for non-small cell lung cancer patients. Drs. Cameron and Wong discuss access to targeted therapies and immunotherapy, the drug approval process in New Zealand, cultural considerations and health disparities affecting lung cancer treatment, and the clinical research infrastructure available in the country. This global perspective highlights how IASLC members face different regional challenges while working toward common goals in advancing lung cancer care.

As part of IASLC's Lung Cancer Considered World Language Series, host Dr. Narjust Florez leads a Spanish-language discussion with three leaders in thoracic oncology across Latin America: Dr. Mónica Castro, Dr. Dolores de la Mata, and Dr. Maritza Ramos Ramírez. They discuss the current landscape of lung cancer in women across the region including unique risk factors and social challenges. The guests share their career paths, the barriers women face in thoracic oncology in Latin America, and their advice for the next generation entering the field.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC. Guest: Li Zhang, MD Professor, Medical Oncology Department Sun Yat-Sen University Cancer Center No Social Guest: Elaine Shum, MD Assistant Professor Director of Cancer Screening Programs New York University Perlmutter Cancer Center

Join Dr. Narjust Florez as she explores complementary and integrative medicine in lung cancer care with leading experts Dr. Ting Bao, Dr. Jun J. Mao, and Dr. Lisa Davis. This episode clarifies the differences between alternative, complementary, and integrative approaches while addressing oncologists' concerns about safety and drug interactions. Learn where to find reliable information, what the research shows about treatments like acupuncture and supplements, and how patients can safely incorporate these therapies into their cancer journey. Guests: Ting Bao, MD, MS, FSIO Co-Director, Leonard P. Zakim Center for Integrative Therapies and Healthy Living Member of the Faculty, Harvard Medical School Dana-Farber Cancer Institute Jun J. Mao, MD, MSCE Chief, Integrative Medicine Service Laurance S. Rockefeller Chair in Integrative Medicine Professor of Medicine, Weill Cornell Medicine Memorial Sloan Kettering Cancer Center Lisa Davis, PharmD, FCCP, BCPS, BCOP, Clinical Professor, Pharmacy Practice & Science The University of Arizona, R. Ken Coit College of Pharmacy

As part of IASLC's Lung Cancer Considered world language series, host Dr. Narjust Florez discusses the role of complementary medicine in cancer care in Spanish with Dr. Cittim Bernardo Palomares and Dr. Eduardo Rios-Garcia. They discuss the role of integrative medicine in lung cancer, how to access accurate information, and the benefits of certain forms of complementary and integrative medicine for patients and their caregivers.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Elene Mariamidze moderates a discussion in Georgian about highlights from the conference with Dr. Salome Begijanashvili, Dr. Beka Shubitidze, and Dr. Mariam Tchiabrishvili.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez speaks with two remarkable young lung cancer advocates Samantha Murell and Megan Flanagan, who are redefining what it means to live with the disease. They share their journeys from diagnosis to advocacy, shedding light on the challenges young patients face, breaking misconceptions, and offering hope to others along the way.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Zsolt Megyesfalvi moderates a discussion in Hungarian about highlights from the conference with Dr. Zsuzsanna Keleman, Dr. Lilla Horvath, and Dr. Gyula Ostoros.

This episode of Lung Cancer Considered covers highlights from the 2025 ESMO Annual Meeting held October 17th to the 21st in Berlin, Germany. Guests are: Dr. Xiuning Le from MD Anderson Cancer Center in Houston, Texas. Dr. Pedro Rocha from Vall d'Hebron University Hospital in Barcelona, Spain. Dr. Riyaz Shah, a consultant medical oncologist at the Kent Oncology Centre in the United Kingdom.

In this episode of Lung Cancer Considered, Dr. Narjust Florez leads a discussion with Ann Fish-Steagall and Amanda Nerstad about the 2025 Lung Cancer Hope Summit. The team discusses highlights from the meeting, including groundbreaking research, innovative treatments, and patient advocacy.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Helena Linardou moderates a discussion in Greek about highlights from the conference with Dr. Foteinos-Ioannis Dimitrakopoulos and Dr. Evangelos Sarris.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC. Guest: Dr. Hossein Borghaei, DO, MS Chief, Division of Thoracic Medical Oncology Professor, Department of Hematology/Oncology Fox Chase Cancer Center

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Riad Abdeljalil, Dr. Khaled Abdel Aziz, Dr. Ashraf Abdel Ghani, Dr. Ahmed Rabea, and Dr. Hussein Soudy.

As part of IASLC's ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Lizza Hendriks moderates a discussion in Dutch with Dr. Marthe Paats and Dr. Gerrina Ruiter on the treatment of EGFR non-small cell lung cancer.

Lung Cancer Considered: Targeting EGFR NSCLC by IASLC

Lung Cancer Considered in Japanese---2025 WCLC Highlights by IASLC

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Min Hee Hong. Guest Host: Chul Kim, MD, MPH Thoracic Medical Oncologist and Associate Professor Georgetown University Instagram: @fe0120 Guest Name(s) & Title(s): Jeongmin Seo, MD, MSc Assistant Professor, Medical Oncology Seoul National University Bundang Hospital Min Hee Hong, MD Associate Professor, Yonsei Cancer Center Severance Hospital, Seoul

IASLC Lung Cancer Considered: FDA Approval: Subcutaneous Immunotherapy by IASLC

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, guest host Dr. Kuan Yu Chen moderates a discussion in Mandarin with Dr. Bin-Chi Liao and Dr. Jeng-Sen Tseng, leading lung cancer experts in Taiwan, who share their perspectives on key highlights from the conference.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Clarissa Baldotto, Dr. Lilian Faroni, Dr. Maria Cecilia Mathias, and Dr. Wiliiam William, Jr.

In this episode, recorded live in Spanish at WCLC 2025, Dr. Diego Carrillo reflects on his experiences as a junior faculty member at WCLC 2025. In conversation with host Dr. Narjust Florez, they discuss conference activities, research highlights, and how WCLC helps junior faculty build their networks and shape the future of lung cancer care and research.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Alona Zer moderates a discussion in Hebrew about highlights from the conference with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about highlights from the conference with Dr. Laura Mezquita and Dr. Jorge Alatorre Alexander.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.

The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.

In this episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu share tips for first-time attendees of the World Conference on Lung Cancer (WCLC). Recorded live at WCLC 2025, hear their 10 key recommendations to make the most of your experience, including advice on how to sneak self-care into your busy conference schedule.

LCC in Mandarin: Neoadjuvant and Perioperative Therapy for Locally Advanced NSCLC by IASLC

IASLC - ALK Positive Summit by IASLC

LCC in Greek: Virtual Tumor Board - ALK NSCLC by IASLC

Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy by IASLC

LCC in Cantonese: Novel Treatment for Advanced EGFR Mutant Lung Cancer by IASLC

FDA Approval: Zongertinib for HER2 Mutant NSCLC by IASLC

As part of IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Asrar AlAhmadi and Dr. Maya Khalil. The group discusses the journey and career development of Arabic women in the field of thoracic oncology.

Artificial Intelligence (AI) and Lung Cancer Treatment Decisions by IASLC

Artificial Intelligence (AI) and Lung Cancer Treatment Decisions by IASLC